港股上市公司百奥赛图-B（02315.HK）今日盘中大涨8.81%，引发市场广泛关注。截至发稿，该股报价25.56港元，成交额达1402万港元。
此轮涨势主要受公司近期发布的亮眼中期业绩推动。百奥赛图-B公布截至2025年6月30日止6个月的财报显示，集团收益达人民币6.21亿元，同比增长51.3%；股东应占溢利4799.9万元，实现扭亏为盈。其中，临床前产品与服务业务收入增长56.9%，抗体发现业务收入增长37.8%，两大核心业务均呈现强劲增长态势。
市场分析人士指出，百奥赛图-B凭借全球领先的基因编辑技术，成功构建了以创新动物模型和抗体分子转让开发为核心的双引擎增长模式。公司通过RenMice系列全人抗体小鼠平台、"千鼠万抗"计划及全球化的专利网络，已在技术和专利层面构筑起双重护城河，形成难以复制的竞争壁垒。随着公司加速确立"全球新药发源地"的行业地位，其长期成长价值和投资吸引力持续提升，这也是推动股价上涨的重要因素。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.